Evolus (EOLS) Notes Payables (2017 - 2021)

Evolus' (EOLS) quarterly Notes Payables came in at $20.0 million in Q3 2021, up 1.54% on a QoQ basis from $19.6 million in Q2 2021.

Evolus (EOLS) Notes Payables (2017 - 2021) Analysis & Trends

Evolus (EOLS) has 3 years of Notes Payables data on file, last reported at $20.0 million in Q3 2021.

Quarterly Notes Payables changed N/A year-over-year to $20.0 million in Q3 2021, while the trailing twelve-month figure through Sep 2021 was $20.0 million (changed N/A YoY) and the FY2020 annual result came in at $19.1 million, changed N/A from the prior year.
Notes Payables advanced to $20.0 million in Q3 2021, from $19.6 million in the prior quarter.
In the past five years, Notes Payables ranged from a high of $138.7 million in Q4 2017 to a low of $19.1 million in Q4 2020.
A 3-year average of $43.3 million and a median of $19.6 million in 2021 frame the typical range for Notes Payables.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.83 Bn	42.86 Bn	-
2	Teva Pharmaceutical Industries	42.87 Bn	39.22 Bn	2.15 Bn
3	Zoetis	31.41 Bn	29.73 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.55 Bn	22.75 Bn	5.10 Bn
5	United Therapeutics	22.08 Bn	19.42 Bn	683.80 Mn
6	Viatris	18.73 Bn	17.84 Bn	1.46 Bn
7	Neurocrine Biosciences	15.44 Bn	15.05 Bn	935.80 Mn
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.11 Bn	9.94 Bn	-
10	Evolus	552.49 Mn	507.32 Mn	57.18 Mn

Download Data